Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2

NCT01123083 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

179

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 1

Interventions

BIOLOGICAL: Otelixizumab
BIOLOGICAL: Placebo

Sponsor

GlaxoSmithKline

Collaborators

[object Object]